Human immunodeficiency virus reverse transcriptase and protease sequence database
暂无分享,去创建一个
Bryan Chan | Robert W. Shafer | Derek Stevenson | R. Shafer | Bryan Chan | Jaideep Ravela | Derek Stevenson | M. J. Gonzales | Soo-Yon Rhee | Rami Kantor | Bradley J. Betts
[1] J Theiler,et al. Limitations of a molecular clock applied to considerations of the origin of HIV-1. , 1998, Science.
[2] Matthew J. Gonzales,et al. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs , 2001, Nucleic Acids Res..
[3] Jianping Ding,et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.
[4] D J Hu,et al. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. , 1996, JAMA.
[5] Robert W. Shafer,et al. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries , 2000, Nature Medicine.
[6] T. Merigan,et al. Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients , 1998, Annals of Internal Medicine.
[7] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[8] J. Erickson,et al. Structural mechanisms of HIV drug resistance. , 1996, Annual review of pharmacology and toxicology.
[9] John W. Mellors,et al. Human retroviruses and AIDS 1996. A compilation and analysis of nucleic acid and amino acid sequences , 1997 .
[10] Eric Hunter,et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.
[11] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[12] D. Katzenstein,et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. , 1994, The Journal of infectious diseases.
[13] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[14] Christos J. Petropoulos,et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.
[15] Brendan Larder,et al. A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.
[16] G. Learn,et al. Maintaining the integrity of human immunodeficiency virus sequence databases , 1996, Journal of virology.